M1 Kliniken stock: fair value
M12.DEThe fair value of M1 Kliniken under our model is $47.69, the price is 54% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $34.07 and expensive above $79.49 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $71.83 (cash-flow model) and $23.55 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $41.49, at 6.1% it would be $57.02.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 2.1%. Discounted at 7.1% (floor: government bond yield 2.1% plus 5 percentage points, since beta 0.8 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $71.83 per share: free cash flow for the next ten years, each year discounted to today at 7.1%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 7.1%) |
|---|---|---|---|---|
| 2026 | $49.07M | extrapolated at 18.9% | 0.9334 | $45.8M |
| 2027 | $55.88M | extrapolated at 13.9% | 0.8712 | $48.68M |
| 2028 | $61.67M | extrapolated at 10.4% | 0.8131 | $50.14M |
| 2029 | $66.53M | extrapolated at 7.9% | 0.7589 | $50.49M |
| 2030 | $70.63M | extrapolated at 6.2% | 0.7083 | $50.03M |
| 2031 | $74.14M | extrapolated at 5.0% | 0.6611 | $49.01M |
| 2032 | $77.19M | extrapolated at 4.1% | 0.6171 | $47.63M |
| 2033 | $79.9M | extrapolated at 3.5% | 0.5760 | $46.02M |
| 2034 | $82.38M | extrapolated at 3.1% | 0.5376 | $44.29M |
| 2035 | $84.71M | extrapolated at 2.8% | 0.5017 | $42.5M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $474.6M |
| Terminal value: cash flow 2035 × (1 + 2.1%) / (7.1% − 2.1%) | $1.73B |
| Present value of terminal value (× 0.5017) | $868.2M |
| Equity value (sum plus present value of terminal value) | $1.34B |
| Shares (diluted) | 18.69M |
| Value per share (equity value divided by shares) | $71.83 |
| Earnings per share, last twelve months | $1.20 |
| × 19.6 (industry P/E) | $23.55 |
| Fair value (average of both parts) | $47.69 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.